Key result
Retinal imaging may clarify shared microvascular mechanisms between schizophrenia and cardiovascular disease.
Why the study?
It is unclear if individuals with schizophrenia have an underlying liability to cardiovascular diseases or if these diseases result from psychotic illness and its treatment, with a lack of studies directly visualizing vasculature in early illness and unaffected relatives.
Retinal imaging is proposed as a novel tool to directly visualize vasculature and study the underlying liability to cardiovascular disease in early-stage schizophrenia.
Early CVD screening may be prudent in first-episode schizophrenia; leaves open inherent liability versus illness-related factors.
Despite evidence that individuals with schizophrenia are disproportionately affected by cardiovascular and cerebrovascular diseases, it is unclear if individuals with schizophrenia have an underlying liability to cardiovascular diseases or if these diseases are a consequence of psychotic illness (e.g., antipsychotic medications, sedentary lifestyle). To resolve this, we must study cardiovascular disease risk factors in individuals in the early stages of illness with limited exposure to antipsychotic medications (i.e., individuals with first-episode psychosis) and in unaffected relatives of individuals with schizophrenia. Here we review evidence of cardiovascular risk in individuals with first-episode psychosis and in unaffected relatives of individuals with schizophrenia. We identify a gap in research on cardiovascular risk in these populations, namely the lack of studies that directly visualize the vasculature, and we introduce a novel technology, retinal imaging, that may be useful for directly visualizing the vasculature and clarifying pathophysiological mechanisms that underlie both schizophrenia and cardiovascular disease. We conclude with suggestions for priorities in future research using retinal imaging.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2017) conducted a review in Schizophrenia and cardiovascular disease. Retinal imaging was evaluated. Retinal imaging is a novel technology that may be useful for directly visualizing the vasculature and clarifying pathophysiological mechanisms underlying both schizophrenia and cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: